肝龙胶囊联合水飞蓟宾胶囊对肝纤维化大鼠的治疗作用  

Therapeutic Effect of Ganlong Capsule Combined with Silybin Capsule on Hepatic Fibrosis in Rats

作　　者：国超 李辉 杨强丽 邵明园 曹昌娥 赖泳 GUO Chao;LI Hui;YANG Qiang-li;SHAO Ming-yuan;CAO Chang-e;LAI Yong(College of Pharmacy and chemistry,Dali University,Dali,Yunnan,671000,China;Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D,Dali,Yunnan,671000,China)

机构地区：[1]大理大学药学与化学学院药理学教研室,云南大理671000 [2]云南省昆虫生物医药,云南大理671000

出　　处：《动物医学进展》2019年第5期49-53,共5页Progress In Veterinary Medicine

基　　金：云南省教育厅科学研究基金重大专项项目(ZD2014013);云南省教育厅科学研究基金项目(2016YJS120)

摘　　要：观察肝龙胶囊联合水飞蓟宾胶囊对肝纤维化大鼠的治疗效果,探讨肝龙胶囊是否对水飞蓟宾胶囊抗肝纤维化具有增效的作用。用猪血清制备大鼠肝纤维化模型,水飞蓟宾胶囊临床给药剂量单用及联合不同剂量肝龙胶囊处理肝纤维化大鼠,通过试剂盒及酶联免疫吸附试验(ELISA)检测大鼠血清和肝组织内肝纤维化标志物透明质酸(hyaluronic acid,HA)、层黏素(laminin,LN)、血清Ⅲ型前胶原氨基端肽(procollagenⅢN-termi,PCⅢ)、Ⅳ型胶原(typeⅣcollagen,Ⅳ-C)及转化生长因子β1(transforming growth factor-β,TGF-β1)、Ⅰ型胶原(collagen typeⅠ,Col-Ⅰ)的含量,以及肝脏内丙二醛(malondialdehyde,MDA)、谷草转氨酶(glutamic oxaloacetic transaminase,AST)、谷丙转氨酶(Cereal third transaminase,ALT)、γ-谷氨酰转肽酶(γ-glutamyl transpeptidase,γ-GT)的含量。与模型组比较,各治疗组中大鼠血清肝纤维化标志物的含量均低于模型组(P<0.05);肝龙胶囊与水飞蓟素联合用药与单用水飞蓟宾组相比,可使大鼠血清内HA和TGF-β1的含量显著降低(P<0.05);大鼠肝脏组织中除PCⅢ外,其余血清肝纤维化标志物的含量治疗组均低于模型组。肝组织中的γ-GT和ALT高剂量联合给药组显著降低,AST无显著差异,MDA中剂量联合给药组显著升高。说明肝龙胶囊可增强水飞蓟宾胶囊对猪血清性肝纤维化大鼠的抗肝纤维化作用。To observe the therapeutic effect of Ganlong capsule combined with silybin capsule on hepatic fibrosis in rats,so as to study whether silibinin capsule combining with Ganlong capsule have the function of improving the effect and decreasing the toxicity,rat liver fibrosis models were prepared with pig serum;hepatic fibrotic rats were treated with silibinin capsule clinical dosage group combining with different concentrations of Ganlong capsule;the liver function was detected by kit;enzyme linked immunosorbent assay (ELISA) was used to detect the liver fibrosis markers in rat sera and liver tissues of hyaluronic acid (HA),laminin (LN),type Ⅲ serum collagen peptide amino end before Ⅲ NP (procollagen Ⅲ N-termi,PCⅢNP),type Ⅳ collagen (Ⅳ- C) and transforming growth factor β1 (TGF-β1),collagen type Ⅰ(Col-Ⅰ) content;and in the liver Malondialdehyde (MDA),glutamic oxaloacetic transaminase (AST),Cereal third transaminase(ALT),γ glutamyl transpeptidase(γ GT) contents.Compared with the model group,the contents of markers of fibrosis in the sera of rats from all treatment groups were all lower than the that of model group.The combined use of silibinin capsule and Ganlong capsule was compared with the silibinin group,the combined treatment group can decrease the contents of HA and TGF-β1 in the sera of rats significantly.Except for PC Ⅲ,the contents of serum liver fibrosis markers in the liver tissues of the rats were lower than those in the model group.In vivo,the combined use of silibinin capsule and Ganlong capsule can enhance its anti-haptic fibrosis and can better treat hepatic fibrosis.

关 键 词：水飞蓟宾胶囊 肝龙胶囊 肝纤维化 增效 

分 类 号：S852.2[农业科学—基础兽医学] S859[农业科学—兽医学]